治疗心肌肥厚药物的进展

[1] Reductioninleftventricu larhypertrophyinhypertensivepatientstreatedwithenalapril,losartanorthecombinationofenalaprilandlosartan. AvanzaACJr,ElAouarLM,MillJG. ArqBrasCardiol . 2000

[2] Regressionofleftventricularhypertrophyinhypertensivepatientsafter1yearoftreatmentwithrilmenidine:adouble blind,randomized,con trolled(versusnifedipine)study. SadowskiZ,SzwedH,KuchWocialA,etal. JHypertens,1998,16(Sup pl3)∶ .

[3] Impactofrecombinanthumanerythropoietintreatmentonleftventricularhypertrophyandcardiacfunctionindialysispatients. MassimettiC,PontilloD,FeriozziS,etal. Blood Purification . 1998

[4] Theinfluenceofdifferentan tihypertensivedrugsonleftventricularhypertrophyinapopula tionsampleofelderlymen. AndrenB ,,LindL,LithellH ,etal. Journal of Human Hypertension . 1999

[5] Characteristicsof9194patientswithleftventricularhypertrophy:theLIFEstudy.LosartanInterventionForEndpointReductioninHypertension. DahlofB,DevereuxRB,JuliusS ,etal. Journal of Hypertension . 1998

[6] AngiotensinⅡantagonismandtheheart:valsar taninleftventricularhypertrophy. ThurmannPA. Cardiology . 1999

[7] Effectsofspironolactoneandan giotensin convertingenzymeinhibitoronleftventricularhyper trophyinpatientswithessentialhypertension. SatoA,SuzukiY,SarutaT. HypertensRes . 1999

[8] Simvastatininhibitscar diachypertrophyandangiotensin convertingenzymeactivityinratswithaorticstenosis. LuoJD,ZhangWW,ZhangGP ,etal. ClinExpPharmacolPhysiol . 1999

[9] OverexpressionofangiotensinⅡtypeIreceptorincardiomyocytesinducescardiachypertrophyandremodeling. ParadisP,DaliYoucefN,ParadisFW,etal. Proceedings of the National Academy of Sciences of the United States of America . 2000

[10] Angiotensinblockingdrugsandtheheartbeyond2000. MorganTO,DelbridgeLM. JAmSocNephrol,1999,11(Suppl)∶ .

[1] Reductioninleftventricu larhypertrophyinhypertensivepatientstreatedwithenalapril,losartanorthecombinationofenalaprilandlosartan. AvanzaACJr,ElAouarLM,MillJG. ArqBrasCardiol . 2000

[2] Regressionofleftventricularhypertrophyinhypertensivepatientsafter1yearoftreatmentwithrilmenidine:adouble blind,randomized,con trolled(versusnifedipine)study. SadowskiZ,SzwedH,KuchWocialA,etal. JHypertens,1998,16(Sup pl3)∶ .

[3] Impactofrecombinanthumanerythropoietintreatmentonleftventricularhypertrophyandcardiacfunctionindialysispatients. MassimettiC,PontilloD,FeriozziS,etal. Blood Purification . 1998

[4] Theinfluenceofdifferentan tihypertensivedrugsonleftventricularhypertrophyinapopula tionsampleofelderlymen. AndrenB ,,LindL,LithellH ,etal. Journal of Human Hypertension . 1999

[5] Characteristicsof9194patientswithleftventricularhypertrophy:theLIFEstudy.LosartanInterventionForEndpointReductioninHypertension. DahlofB,DevereuxRB,JuliusS ,etal. Journal of Hypertension . 1998

[6] AngiotensinⅡantagonismandtheheart:valsar taninleftventricularhypertrophy. ThurmannPA. Cardiology . 1999

[7] Effectsofspironolactoneandan giotensin convertingenzymeinhibitoronleftventricularhyper trophyinpatientswithessentialhypertension. SatoA,SuzukiY,SarutaT. HypertensRes . 1999

[8] Simvastatininhibitscar diachypertrophyandangiotensin convertingenzymeactivityinratswithaorticstenosis. LuoJD,ZhangWW,ZhangGP ,etal. ClinExpPharmacolPhysiol . 1999

[9] OverexpressionofangiotensinⅡtypeIreceptorincardiomyocytesinducescardiachypertrophyandremodeling. ParadisP,DaliYoucefN,ParadisFW,etal. Proceedings of the National Academy of Sciences of the United States of America . 2000

[10] Angiotensinblockingdrugsandtheheartbeyond2000. MorganTO,DelbridgeLM. JAmSocNephrol,1999,11(Suppl)∶ .